A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Completed · Phase 4

Conditions studied: Hypertension, Diabetic Nephropathies

In brief

A number of blood pressure lowering drugs in the class known as angiotensin receptor blockers (ARB) have been shown to slow the decline in kidney function of patients with type 2 diabetes, high blood pressure, and kidney disease. Losartan (COZAAR), is one such drug. The purpose of this research study is to determine if after one year of treatment telmisartan (MICARDIS, GLIOSARTAN, KINZAL, KINZALMONO, PREDXAL, PRITOR, SAMERTAN, TELMISARTAN) 80 mg, another blood pressure lowering drug from the ARB class, is as effective as losartan (COZAAR) 100 mg in reducing the level of urinary protein (indicative of improved kidney function).

Key facts

Study ID

NCT00168857

Run by

Boehringer Ingelheim

People needed

860

Starts

2003-07-09

Last updated by the study team

2023-12-08

Who can join

Age: 21 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
• Age 21-80 years
• Clinical history of type 2 diabetes mellitus, as defined by either:
• Hyperglycaemia not requiring insulin (diet, oral hypoglycaemic agents and metformin if patients serum creatinine levels were within normal limits.)
• Hyperglycaemia requiring insulin with: no history of diabetic ketoacidosis AND with either the period between diagnosis and insulin usage >1 year or elevated fasting or stimulated C-peptide level
• Glycosylated haemoglobin A1 (HbA1c) ≤10%
• Diabetic nephropathy, as defined by:
• serum creatinine at Screening (Visit 1) ≤265 μmol/L (3.0 mg/dL) in women and ≤283 μmol/L (3.2 mg/dL) in men
• urinary protein/creatinine ratio ≥700 mg/g (measured in spot urine) during the run-in phase (Visit 2 or Visit 5 retest)
• Hypertension at screening, as defined by either:
• Mean systolic blood pressure (SBP) >130 mmHg and/or mean diastolic blood pressure (DBP) >80 mmHg in untreated patients
• Patients currently receiving antihypertensive medication (i.e. medications specifically prescribed to treat hypertension)
• Ability to stop current antihypertensive therapy with Angiotensin Converting Enzyme Inhibitor (ACE-Is), Angiotensin Receptor Blockers (ARBs) and direct vasodilators, and to stop chronic immunosuppressive therapy and current therapy with metformin without risk to the patient (Investigator's discretion).
• All female patients had to have negative results from the urine pregnancy test (UPT) at Visits 1 and 6 in order to be able to continue in the study.

You may not qualify if…

• Pre-menopausal women (last menstruation ≤1 year prior to signing informed consent) who:
• were not surgically sterile or
• were nursing or pregnant or
• were of child-bearing potential and were not practicing acceptable methods of birth control, or did not plan to continue practicing an acceptable method throughout the study (Note: Acceptable methods of birth control included transdermal patch, intra-uterine device, oral, implantable or injectable contraceptives) AND did not agree to periodic urine pregnancy testing (UPT) during participation in the study. No exceptions were made.
• Type 1 diabetes mellitus
• Increase of serum creatinine >35% between Visit 1 (Screening) and Visit 5. If creatinine was increased >35% at Visit 5, the measurement was to be repeated within five calendar days and if the increase was confirmed, the patient had to be excluded from the trial for safety reasons.
• Non-diabetic renal disease
• Congestive heart failure (New York Heart Association functional class III or IV)
• Unstable angina, myocardial infarction, coronary artery bypass graft surgery, or percutaneous coronary intervention within the last three months prior to signing the informed consent form
• Stroke or transient ischaemic attack within the last six months prior to signing the informed consent form
• Hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve
• Further exclusion criteria apply

Where it is running

• Boehringer Ingelheim Investigational Site — Little Rock, Arkansas, United States
• Boehringer Ingelheim Investigational Site — Lancaster, California, United States
• Boehringer Ingelheim Investigational Site — Los Angeles, California, United States
• VA of Greater Los Angeles — Los Angeles, California, United States
• UCI Medical Center — Orange, California, United States
• VA San Diego Healthcare System — San Diego, California, United States
• Boehringer Ingelheim Investigational Site — Santa Ana, California, United States
• UCLA Medical Center — Sylmar, California, United States
• Torrance Clinical Research — Torrance, California, United States
• University of Colorado Health Sciences Center — Denver, Colorado, United States
• Boehringer Ingelheim Investigational Site — Wheat Ridge, Colorado, United States
• George Washington University — Washington D.C., District of Columbia, United States
• Boehringer Ingelheim Investigational Site — Hollywood, Florida, United States
• Boehringer Ingelheim Investigational Site — Largo, Florida, United States
• Boehringer Ingelheim Investigational Site — Ocala, Florida, United States
• Boehringer Ingelheim Investigational Site — Pembroke Pines, Florida, United States
• Boehringer Ingelheim Investigational Site — Tampa, Florida, United States
• Boehringer Ingelheim Investigational Site — Atlanta, Georgia, United States
• Medical College of Georgia — Augusta, Georgia, United States
• Rush Presbyterian - St. Lukes Medical Center — Chicago, Illinois, United States
• Boehringer Ingelheim Investigational Site — Des Moines, Iowa, United States
• Louisiana State University Health Science Center — New Orleans, Louisiana, United States
• Boehringer Ingelheim Investigational Site — Shreveport, Louisiana, United States
• Boehringer Ingelheim Investigational Site — Towson, Maryland, United States
• Boehringer Ingelheim Investigational Site — Montgomery, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.